Literature DB >> 21864076

Antiganglioside antibodies in Guillain-Barré syndrome and its related conditions.

Nortina Shahrizaila1, Nobuhiro Yuki.   

Abstract

Guillain-Barré syndrome (GBS) is typically classified into two major subtypes: acute inflammatory demyelinating neuropathy and acute motor axonal neuropathy. Its most recognizable variant is Fisher syndrome. The last two decades have seen considerable advances in our understanding of GBS. Of note, various autoantibodies against ganglioside antigens have been identified and found to have significant associations with the axonal forms of GBS and Fisher syndrome. In this article, we discuss the different clinical presentations in GBS and the role of antiganglioside antibodies in their underlying pathogenesis. We also discuss the impact that antiganglioside antibodies have had in the development of experimental models and treatment modalities in GBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864076     DOI: 10.1586/ern.11.114

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

1.  Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes.

Authors:  Nortina Shahrizaila; Norito Kokubun; Setsu Sawai; Thirugnanam Umapathi; Yee-Cheun Chan; Satoshi Kuwabara; Koichi Hirata; Nobuhiro Yuki
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

2.  Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma.

Authors:  Jonathan J D Baird-Gunning; Dinushi Weerasinghe; Matthew Silsby; Yash Gawarikar; Matteo S Carlino; Jessica L Smith; Steve Vucic
Journal:  Neurohospitalist       Date:  2018-05-27

3.  Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).

Authors:  Denong Wang; Roopa Bhat; Raymond A Sobel; Wei Huang; Lai-Xi Wang; Tomas Olsson; Lawrence Steinman
Journal:  Drug Dev Res       Date:  2014-03-11       Impact factor: 4.360

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.